Basic Information
OrbiMed, founded in 1989, is one of the largest investment firms globally that focuses on the biopharmaceutical field. Currently, the firm manages approximately $14 billion in assets and has successfully invested in over 450 companies worldwide.OrbiMed Asia manages three private equity funds focused on the biopharmaceutical sector in Asia, with a total of about $1 billion. It has invested in 40 companies, including Zai Lab, Genewiz, Admera Health, Eddingpharm, and Aokang Yicheng, among other outstanding enterprises. OrbiMed's secondary market fund has around $2 billion in investments in Asia.